In the Exforge case, Faruqi & Farqui represents a pharmaceutical wholesaler and a proposed class of direct purchasers of the hypertension drug, Exforge. The complaint alleges that Novartis entered into a reverse payment agreement with Par to delay Par’s generic launch. In exchange, Novartis promised not to launch an authorized generic version of Exforge for the first 180 days Par was on the market.
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.
Filed on 06/22/2018
1617 JFK Boulevard, Suite 1550
19103 Philadelphia, Pennsylvania
Phone (215) 277-5770
Fax (215) 277-5771
Joseph T. Lukens email@example.com Phone (215) 277-5770 Fax (215) 277-5771
Peter Kohn firstname.lastname@example.org Phone (215) 277-5770 Fax (215) 277-5771